Abstract
In neurological insults, such as cerebral ischemia and traumatic brain injury, complex molecular mechanisms involving inflammation and apoptosis are known to cause severe neuronal cell loss, emphasizing the necessity of developing therapeutic strategies targeting simultaneously these two processes. Over the last decade, numerous in vitro and in vivo studies have demonstrated the unique therapeutical potential of pituitary adenylate cyclase-activating polypeptide (PACAP) for the treatment of neuronal disorders involving apoptotic cell death and neuroinflammation. The neuroprotective activity of PACAP is based on its capacity to reduce the production of deleterious cytokines from activated microglia, to stimulate the release of neuroprotective agents from astrocytes and to inhibit proapoptotic intracellular pathways. However, the use of PACAP as a clinically applicable drug is hindered by its peptidic nature. As most natural peptides, native PACAP shows poor metabolic stability, low bioavailability, inadequate distribution and rapid blood clearance. Moreover, injection of PACAP to human can induce peripheral adverse side effects. Therefore, targeted chemical modifications and/or conjugation of PACAP to different macromolecules are required to improve the pharmacokinetic and pharmacological properties of PACAP. This review presents the chemical, biochemical and pharmacological strategies that are currently under development to convert PACAP from a hypophysiotropic neurohormone into a clinically relevant neuroprotective drug.
Keywords: PACAP, VIP, Neuroprotection, Stroke, Traumatic brain injury, G protein-coupled receptor, Bioactive conformation, Peptide drug design, hypophysiotropic, methionine, insulinotropic, helodermin, N-glycosylation, inositol, dromotropic, phosphorylation, apurinic, threonine, encephalomyelitis, inducesthe
Current Pharmaceutical Design
Title: Strategies to Convert PACAP from a Hypophysiotropic Neurohormone Into a Neuroprotective Drug
Volume: 17 Issue: 10
Author(s): S. Bourgault, D. Chatenet, O. Wurtz, N. D. Doan, J. Leprince, H. Vaudry, A. Fournier and D. Vaudry
Affiliation:
Keywords: PACAP, VIP, Neuroprotection, Stroke, Traumatic brain injury, G protein-coupled receptor, Bioactive conformation, Peptide drug design, hypophysiotropic, methionine, insulinotropic, helodermin, N-glycosylation, inositol, dromotropic, phosphorylation, apurinic, threonine, encephalomyelitis, inducesthe
Abstract: In neurological insults, such as cerebral ischemia and traumatic brain injury, complex molecular mechanisms involving inflammation and apoptosis are known to cause severe neuronal cell loss, emphasizing the necessity of developing therapeutic strategies targeting simultaneously these two processes. Over the last decade, numerous in vitro and in vivo studies have demonstrated the unique therapeutical potential of pituitary adenylate cyclase-activating polypeptide (PACAP) for the treatment of neuronal disorders involving apoptotic cell death and neuroinflammation. The neuroprotective activity of PACAP is based on its capacity to reduce the production of deleterious cytokines from activated microglia, to stimulate the release of neuroprotective agents from astrocytes and to inhibit proapoptotic intracellular pathways. However, the use of PACAP as a clinically applicable drug is hindered by its peptidic nature. As most natural peptides, native PACAP shows poor metabolic stability, low bioavailability, inadequate distribution and rapid blood clearance. Moreover, injection of PACAP to human can induce peripheral adverse side effects. Therefore, targeted chemical modifications and/or conjugation of PACAP to different macromolecules are required to improve the pharmacokinetic and pharmacological properties of PACAP. This review presents the chemical, biochemical and pharmacological strategies that are currently under development to convert PACAP from a hypophysiotropic neurohormone into a clinically relevant neuroprotective drug.
Export Options
About this article
Cite this article as:
Bourgault S., Chatenet D., Wurtz O., D. Doan N., Leprince J., Vaudry H., Fournier A. and Vaudry D., Strategies to Convert PACAP from a Hypophysiotropic Neurohormone Into a Neuroprotective Drug, Current Pharmaceutical Design 2011; 17 (10) . https://dx.doi.org/10.2174/138161211795589337
DOI https://dx.doi.org/10.2174/138161211795589337 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Electrolyte Permeability by Herbal Monomers in Edematous Disorders
Current Pharmaceutical Design Structural Characterization, Biological Effects, and Synthetic Studies on Xanthones from Mangosteen (Garcinia mangostana), a Popular Botanical Dietary Supplement
Mini-Reviews in Organic Chemistry Oral Targeting of Protein Kinase C Receptor: Promising Route for Diabetic Retinopathy?
Current Drug Delivery Mitochondrial Targeting for Development of Novel Drug Strategies in Brain Injury
Central Nervous System Agents in Medicinal Chemistry Role of Adenosine Kinase Inhibitor in Adenosine Augmentation Therapy for Epilepsy: A Potential Novel Drug for Epilepsy
Current Drug Targets Carotid Artery Disease: Current Concepts on Endothelial Dysfunction and Matrix Remodeling
Current Drug Therapy Neuropharmacology of Cannabinoid System: From Basic Science to Clinical Applications
Current Neuropharmacology Transplantation of Adipose Tissue-Derived Stem Cells for Treatment of Focal Cerebral Ischemia
Current Neurovascular Research Coumarins as Antioxidants
Current Medicinal Chemistry A Critical Evaluation of Adenosine A2A Receptors as Potentially “Druggable” Targets in Huntingtons Disease
Current Pharmaceutical Design Ultrasound Imaging of Muscle-tendon Architecture in Neurological Disease: Theoretical Basis and Clinical Applications
Current Medical Imaging Inflammatory Mechanisms and Oxidative Stress as Key Factors Responsible for Progression of Neurodegeneration: Role of Brain Innate Immune System
CNS & Neurological Disorders - Drug Targets MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Imbalance and Management of Iron Homeostasis and the Intervention of Chinese Medicine in Intracerebral Hemorrhage: A Review
Current Traditional Medicine Cross-Talk between Oxidative Stress and Pro-Inflammatory Cytokines in Acute Pancreatitis: A Key Role for Protein Phosphatases
Current Pharmaceutical Design Immunotherapy in Allergies: An Update
Inflammation & Allergy - Drug Targets (Discontinued) Microaspiration in Intubated Critically Ill Patients: Diagnosis and Prevention
Infectious Disorders - Drug Targets Omega-3 Polyunsaturated Fatty Acids and Depression: A Review of the Evidence
Current Pharmaceutical Design The Integral Nuclear Membrane Protein Nurim Plays a Role in the Suppression of Apoptosis
Current Molecular Medicine